|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunosuppressant
|
|
gptkbp:administeredBy
|
auto-inflammatory diseases
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AC08
|
|
gptkbp:brand
|
gptkb:Ilaris
|
|
gptkbp:CASNumber
|
89138-09-0
|
|
gptkbp:contraindication
|
active infections
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:halfLife
|
~26 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
canakinumab
|
|
gptkbp:isMonoclonalAntibodyType
|
gptkb:human
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IL-1β
|
|
gptkbp:mechanismOfAction
|
interleukin-1 beta inhibitor
|
|
gptkbp:molecularWeight
|
~150 kDa
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1201836
DB06170
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
abdominal pain
infections
neutropenia
injection site reactions
|
|
gptkbp:UNII
|
JYG2O7IK1G
|
|
gptkbp:usedFor
|
gptkb:Still's_disease
gptkb:cryopyrin-associated_periodic_syndromes
systemic juvenile idiopathic arthritis
gout flares
|
|
gptkbp:bfsParent
|
gptkb:CANTOS_trial
gptkb:interleukin-1
|
|
gptkbp:bfsLayer
|
6
|